Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436606 | 0.94 | HSD11B1 (0.45) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 | |
| SCHEMBL15023086 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A3HSD11B1SLC6A2PTGDR | |
| SCHEMBL435746 | 0.81 | DRD2 (0.41) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 | |
| SCHEMBL435386 | 0.81 | HSD11B1 (0.66) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 | |
| SCHEMBL624643 | 0.79 | HSD11B1 (0.63) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 | |
| SCHEMBL15043699 | 0.78 | SLC6A4 (0.50) | SLC6A4SLC6A3ALDH1A1SLC6A2HTR2C | |
| SCHEMBL3633468 | 0.76 | HSD11B1 (0.68) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 | |
| SCHEMBL12836587 | 0.74 | SLC6A4 (0.54) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 | |
| SCHEMBL15042324 | 0.74 | SLC6A4 (0.46) | SLC6A4SLC6A3ALDH1A1SLC6A2HTR2C | |
| SCHEMBL7177946 | 0.72 | ALDH1A1 (0.61) | SLC6A4SLC6A3HSD11B1ALDH1A1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187437-B2 | Substituted oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187437-B2 | Substituted oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187437-B2 | Substituted oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2619190-B1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2619190-B1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| EP-2595969-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012040532-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040532-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A4 2567/4885SLC6A3 2098/4885HSD11B1 623/4885 |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A4 2698/4885SLC6A3 2766/4885HSD11B1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.